|
|
|
|
LEADER |
01881nam a2200385 u 4500 |
001 |
EB002000607 |
003 |
EBX01000000000000001163508 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
100 |
1 |
|
|a Wells, Charlotte
|
245 |
0 |
0 |
|a High dose influenza vaccine for adults
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Charlotte Wells, Aleksandra Grobelna
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2019, January 8, 2019
|
300 |
|
|
|a 1 PDF file (45 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Comparative Effectiveness Research
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Influenza Vaccines / economics
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Aged
|
653 |
|
|
|a Treatment Outcome
|
653 |
|
|
|a Influenza, Human / drug therapy
|
653 |
|
|
|a Influenza Vaccines / therapeutic use
|
653 |
|
|
|a Guidelines as Topic
|
700 |
1 |
|
|a Grobelna, Aleksandra
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK541617
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 140
|
082 |
0 |
|
|a 330
|
520 |
|
|
|a The purpose of this review is to evaluate the comparative clinical evidence of high-dose influenza vaccination compared with standard-dose (and double-dose) influenza vaccine or placebo. Additionally, the comparative cost effectiveness and evidence-based guidelines were analyzed to facilitate and support decision making with regards to high-dose influenza vaccine
|